Abstract:Abstract Background Immune checkpoint-inhibitors have become a standard treatment for clear cell renal cell carcinoma (ccRCC). However, responses to checkpoint-inhibition are heterogeneous and many patients are resistant or eventually develop resistance. A better understanding of functional mechanisms governing immune responses in ccRCC is needed to identify biomarkers for therapeutic responses and to unravel novel therapeutic targets to overcome primary or acquired resistance to therapies. Methods We developed a fully human explant model derived from freshly resected ccRCC tissue (Fig. 1A). Our tissue explant model preserves all components of the tumor microenvironment including not only tumor cells, but also the immune cell compartment as well as tumor-stroma and -vasculature in culture (Fig. 1B). Following treatment with combined checkpoint-inhibition (Nivolumab plus Ipilimumab) or an anti-CCR5 inhibitor (Maraviroc), the tissue explants were analyzed by immunohistochemistry staining and multiplex cytokine profiling of 50 cytokines. Spatial and functional insights were incorporated in an agent-based in silico model (PhysiCell, Ghaffarizadeh et al., PLoS Comput. Biol., 2018) for unlimited exploration of functional cellular dynamics in the tumor microenvironment (Fig. 1D). Results Immunohistochemical analyses and cytokine profiling of ccRCC-tissue explants showed heterogeneous immune responses among different patients and indicated an impaired cytotoxic T cell response following checkpoint-inhibition (Fig. 1C). Spatial analyses of immune cell populations revealed clusters of CD8+ T cells and CD163+ macrophages localized closely to CD31+ endothelial cells. Further characterization of the tumor microenvironment revealed high CCR5-expression in the tumor, particularly on the tumor blood vessels (Fig. 1B). Treatment of the tissue explants with the anti-CCR5 inhibitor Maraviroc led to an increase of CD8+ T cells and cytotoxic cytokines (Granzyme B, IFNgamma, TNFalpha, IFNalpha2) in the tumor in comparison to checkpoint-inhibition (Fig. 1C). Spatial and functional information from cultured ccRCC-tissue explants were integrated into an agent-based in silico model of the ccRCC tumor microenvironment, which includes tumor cells, T cells, macrophages and endothelial cells (Fig. 1D). In silico simulation of different immune cell modulating treatment conditions showed an increase of T cells and cytotoxic cytokines upon blockade of the interaction between T cells with endothelial cells or macrophages (Fig. 1E). Conclusions Our combined ex vivo and in silico analyses provide evidence for immunosuppression in the ccRCC tumor microenvironment mediated by macrophages and endothelial cells. CCR5 was shown to be a potential target to overcome immune resistance to checkpoint-inhibition in ccRCC. Further characterization of immune cell compositions and functional mechanisms in the perivascular area is imperative to enhance therapeutic responses to immunotherapies for ccRCC.

Renal Cell Carcinoma May Evade the Immune System by Converting CD4+Foxp3- T Cells into CD4+CD25+Foxp3+ Regulatory T Cells: Role of Tumor COX-2-derived PGE2

The Clinical Application of COX-2 Inhibitors May Strengthen the Sensitivity of Renal Cell Carcinoma to Immunotherapy

The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma

Human Epithelial Ovarian Carcinoma Cell-Derived Cytokines Cooperatively Induce Activated Cd4+Cd25-Cd45ra+Naive T Cells To Express Forkhead Box Protein 3 And Exhibit Suppressive Ability In Vitro

COX-2 inhibitors combined with IL-2 strengthened sensitivity of immunotherapy to mice renal cell carcinoma

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.

circFOXO3 Induced by KLF16 Modulates Clear Cell Renal Cell Carcinoma Growth and Natural Killer Cell Cytotoxic Activity through Sponging miR-29a-3p and miR-122-5p

Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner.

Molecular and Cellular Pathobiology FoxO Transcription Factors Promote AKT Ser 473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI 3 K – AKT Pathway

Supplementary Methods and Figures Legends from FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway

Prognostic model for clear-cell renal cell carcinoma based on natural killer cell-related genes.

Phosphodiesterase 4A Confers Resistance to PGE2-mediated Suppression in CD25+ /CD54+ NK Cells.

Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma

ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis

Abstract 2463: Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients

Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma

MP18-03 TUMOR-INFILTRATING CD39+CD8+ T CELLS DETERMINE POOR PROGNOSIS AND IMMUNE EVASION IN CLEAR-CELL RENAL CELL CARCINOMA PATIENTS

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

Skewed T-helper (Th)1/2-and Th17/T Regulatory-Cell Balances in Patients with Renal Cell Carcinoma

30 Synergistic systematic analysis with fully human tissue models and in silico modeling of “copycats” reveals mechanisms of T cell suppression in clear cell renal cell carcinoma

Tumor-derived colorectal cancer organoids induce a unique Treg cell population through direct modulation of CD4+ T cell differentiation.